Abstracts tagged "mTor and metabolism"

Abstract Number: 60 • 2018 ACR/ARHP Annual Meeting
Combined Inhibition of Mechanistic Target of Rapamycin and Glutamine Metabolism Inhibits CD4 T Cell Proliferation and Th17 Differentiation, Facilitates the Expansion of Myeloid-Derived Suppressor Cells, and Synergistically Ameliorates Arthritis in SKG Mice
Yo Ueda¹, Jun Saegusa¹, Tadashi Okano², Sho Sendo¹, Hirotaka Yamada², Kengo Akashi¹, Akira Onishi¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The mechanistic target of rapamycin (mTOR) pathway and glutamine metabolism are activated cooperatively in the differentiation and the activation of inflammatory immune cells such…
Abstract Number: 2675 • 2018 ACR/ARHP Annual Meeting
Age-Related Metabolic Changes Underlie Pro-Inflammatory Lineage Specification and Contribute to Therapeutic Responsiveness to Mechanistic Target of Rapamycin Blockade in SLE
Zhi-Wei Lai¹, Ryan Kelly² and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) patients exhibit T-cell dysfunction which can be reversed by blockade of the mechanistic target of rapamycin (mTOR) with therapeutic efficacy…
Abstract Number: 1321 • 2017 ACR/ARHP Annual Meeting
Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice
Yo Ueda¹, Takaichi Okano¹, Hirotaka Yamada¹, Yoshihide Ichise¹, Ikuko Naka², Soshi Takahashi³, Sho Sendo⁴, Kengo Akashi², Akira Onishi⁵, Jun Saegusa⁴ and Akio Morinobu³, ¹Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells that increase in the pathological state such as tumor or inflammation and have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].